Skip to main content
Top
Published in: BMC Nephrology 1/2017

Open Access 01-12-2017 | Case report

Ultrastructural deposits appearing as “zebra bodies” in renal biopsy: Fabry disease?– comparative case reports

Authors: Precil Diego Miranda de Menezes Neves, Juliana Reis Machado, Fabiano Bichuette Custódio, Maria Luíza Gonçalves dos Reis Monteiro, Shigueo Iwamoto, Marlene Freire, Marisa França Ferreira, Marlene Antônia dos Reis

Published in: BMC Nephrology | Issue 1/2017

Login to get access

Abstract

Background

Fabry Disease (FD) is a genetic disorder caused by alpha-galactosidase A deficiency. Certain drugs, such as hydroxychloroquine, can produce renal deposits that mimic morphological findings seen in FD, characterizing a type of drug-induced renal phospholipidosis.

Case presentation

Case 1: A 28-year-old female patient with systemic lupus erythematosus who had been using hydroxychloroquine for 14 months presented subnephrotic proteinuria. Renal biopsy showed deposits compatible with FD. Neither activity analysis of alpha-galactosidase A nor genetic analysis were available and were not performed. These deposits were not detected in a subsequent renal biopsy three years after withdrawal of the medication, characterizing a possible hydroxychloroquine-induced renal phospholipidosis. Case 2: A 29-year-old male patient presented with acroparesthesia, angiokeratomas, cornea verticillata and subnephrotic proteinuria. Deposits compatible with FD were detected upon renal biopsy. The evaluation of alpha-galactosidase A showed no activity in both blood and leukocytes. Genetic analysis identified an M284 T mutation in exon 6, and such mutation was also found in other family members.

Conclusion

Clinical investigation is necessary in suspected cases of Fabry Disease upon renal biopsy in order to confirm diagnosis. Drug-induced renal phospholipidosis should be considered in differential diagnosis in cases with intracellular osmiophilic, lamellar inclusions in electron microscopy.
Literature
2.
go back to reference Branton M, Schiffmann R, Kopp J. Natural history and treatment of renal involvement in Fabry Disease. J Am Soc Nephrol. 2002;13:139–43. Branton M, Schiffmann R, Kopp J. Natural history and treatment of renal involvement in Fabry Disease. J Am Soc Nephrol. 2002;13:139–43.
3.
go back to reference Ortiz A, Oliveira JP, Waldek S, et al. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant. 2008;23:1600–7.CrossRefPubMed Ortiz A, Oliveira JP, Waldek S, et al. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant. 2008;23:1600–7.CrossRefPubMed
4.
go back to reference Ortiz A, Oliveira JP, Wanner C, et al. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults. Nat Clin Pract. 2008;4(6):328–36.CrossRef Ortiz A, Oliveira JP, Wanner C, et al. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults. Nat Clin Pract. 2008;4(6):328–36.CrossRef
5.
go back to reference Eng CM, Fletcher J, Wilcox WR, et al. Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis. 2007;30:184–92.CrossRefPubMed Eng CM, Fletcher J, Wilcox WR, et al. Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis. 2007;30:184–92.CrossRefPubMed
6.
go back to reference Wilcox WR, Oliveira JP, Hopkin RJ, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab. 2008;93:112–28.CrossRefPubMed Wilcox WR, Oliveira JP, Hopkin RJ, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab. 2008;93:112–28.CrossRefPubMed
7.
go back to reference Fogo AB, Bostad L, Svarstad E, et al. Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant. 2010;25:2168–77.CrossRefPubMed Fogo AB, Bostad L, Svarstad E, et al. Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant. 2010;25:2168–77.CrossRefPubMed
8.
go back to reference Albay D, Adler SG, Philipose J, et al. Chloroquine-induced lipidosis mimicking Fabry disease. Mod Pathol. 2005;18(5):733–8.CrossRefPubMed Albay D, Adler SG, Philipose J, et al. Chloroquine-induced lipidosis mimicking Fabry disease. Mod Pathol. 2005;18(5):733–8.CrossRefPubMed
9.
go back to reference Bracamonte ER, Kowalewska J, Starr J, et al. Iatrogenic Phospholipidosis Mimicking Fabry Disease. Am J Kidney Dis. 2006;48(5):844–50.CrossRefPubMed Bracamonte ER, Kowalewska J, Starr J, et al. Iatrogenic Phospholipidosis Mimicking Fabry Disease. Am J Kidney Dis. 2006;48(5):844–50.CrossRefPubMed
10.
go back to reference Müller-Höcker J, Schmid H, Weiss M, et al. Chloroquine-induced phospholipidosis of the kidney mimicking Fabry’s disease: case report and review of the literature. Hum Pathol. 2003;34(3):285–9.CrossRefPubMed Müller-Höcker J, Schmid H, Weiss M, et al. Chloroquine-induced phospholipidosis of the kidney mimicking Fabry’s disease: case report and review of the literature. Hum Pathol. 2003;34(3):285–9.CrossRefPubMed
11.
go back to reference Woywodt A, Hellweg S, Schwarz A, et al. A wild zebra chase. Nephrol Dial Transplant. 2007;22(10):3074–7.CrossRefPubMed Woywodt A, Hellweg S, Schwarz A, et al. A wild zebra chase. Nephrol Dial Transplant. 2007;22(10):3074–7.CrossRefPubMed
12.
go back to reference Breunig F, Weidemann F, Strotmann J, et al. Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int. 2006;69:1216–21.CrossRefPubMed Breunig F, Weidemann F, Strotmann J, et al. Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int. 2006;69:1216–21.CrossRefPubMed
13.
go back to reference Biegstraaten M, Arngrímsson R, Barbey F, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis. 2015;10(36):2–10. Biegstraaten M, Arngrímsson R, Barbey F, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis. 2015;10(36):2–10.
14.
go back to reference Azevedo DJ, D’Almeida LO, Silveira RA, et al. Primeiros pacientes do Estado do Rio de Janeiro tratados com a enzima recombinante Agalsidase Beta (Fabrazime). Rev Bras Oftal. 2004;63(4):259–63. Azevedo DJ, D’Almeida LO, Silveira RA, et al. Primeiros pacientes do Estado do Rio de Janeiro tratados com a enzima recombinante Agalsidase Beta (Fabrazime). Rev Bras Oftal. 2004;63(4):259–63.
15.
go back to reference Selvarajah M, Nicholls K, Hewitson TD, Becker GJ. Targeted urine microscopy in Anderson-Fabry Disease: a cheap, sensitive and specific diagnostic technique. Nephrol Dial Transplant. 2011;26:3195–202.CrossRefPubMed Selvarajah M, Nicholls K, Hewitson TD, Becker GJ. Targeted urine microscopy in Anderson-Fabry Disease: a cheap, sensitive and specific diagnostic technique. Nephrol Dial Transplant. 2011;26:3195–202.CrossRefPubMed
16.
go back to reference Reasor MJ, Kacew S. Drug-induced phospholipidosis: are there functional consequences? Exp Biol Med. 2001;226:825–30. Reasor MJ, Kacew S. Drug-induced phospholipidosis: are there functional consequences? Exp Biol Med. 2001;226:825–30.
17.
go back to reference Pintavorn P, Cook WJ. Progressive renal insufficiency associated with amiodarone-induced phospholipidosis. Kidney Int. 2008;74:1354–7.CrossRefPubMed Pintavorn P, Cook WJ. Progressive renal insufficiency associated with amiodarone-induced phospholipidosis. Kidney Int. 2008;74:1354–7.CrossRefPubMed
18.
go back to reference Khubchandani SR, Bichle LS. Hydroxychloroquine induced Phospholipidosis in a case of SLE: The Wolf in Zebra Clothing. Ultrastruct Pathol. 2013;37(2):146–50.CrossRefPubMed Khubchandani SR, Bichle LS. Hydroxychloroquine induced Phospholipidosis in a case of SLE: The Wolf in Zebra Clothing. Ultrastruct Pathol. 2013;37(2):146–50.CrossRefPubMed
19.
go back to reference Sakuraba H, Tsukimura T, Tanaka T, et al. Clinical and biochemical investigation of male patients exhibiting membranous cytoplasmic bodies in biopsied kidney tissues; a pitfall in diagnosis. J Nephropathol. 2015;4(3):91–6.PubMedPubMedCentral Sakuraba H, Tsukimura T, Tanaka T, et al. Clinical and biochemical investigation of male patients exhibiting membranous cytoplasmic bodies in biopsied kidney tissues; a pitfall in diagnosis. J Nephropathol. 2015;4(3):91–6.PubMedPubMedCentral
20.
go back to reference Costa RM, Martul EV, Reboredo JM, et al. Curvilinear bodies in hydroxychloroquine-induced renal phospholipidosis resembling Fabry disease. Clin Kidney J. 2013;0:1–4. Costa RM, Martul EV, Reboredo JM, et al. Curvilinear bodies in hydroxychloroquine-induced renal phospholipidosis resembling Fabry disease. Clin Kidney J. 2013;0:1–4.
21.
go back to reference Neville HE, Maunder-Sewry CA, McDougall J, et al. Chloroquine-induced cytosomes with curvilinear profiles in muscle. Muscle Nerve. 1979;2:376–81.CrossRefPubMed Neville HE, Maunder-Sewry CA, McDougall J, et al. Chloroquine-induced cytosomes with curvilinear profiles in muscle. Muscle Nerve. 1979;2:376–81.CrossRefPubMed
22.
go back to reference Loh AHL, Cohen A. Drug-induced kidney disease: Pathology and current concepts. Ann Acad Med Singap. 2009;38:240–50.PubMed Loh AHL, Cohen A. Drug-induced kidney disease: Pathology and current concepts. Ann Acad Med Singap. 2009;38:240–50.PubMed
23.
go back to reference Zhao F, Dou Y, Liu D, et al. Hydroxychloroquine-induced lipidosis of the kidney mimicking Fabry disease: a case report. Int J Clin Exp Pathol. 2016;9(2):2591–3. Zhao F, Dou Y, Liu D, et al. Hydroxychloroquine-induced lipidosis of the kidney mimicking Fabry disease: a case report. Int J Clin Exp Pathol. 2016;9(2):2591–3.
Metadata
Title
Ultrastructural deposits appearing as “zebra bodies” in renal biopsy: Fabry disease?– comparative case reports
Authors
Precil Diego Miranda de Menezes Neves
Juliana Reis Machado
Fabiano Bichuette Custódio
Maria Luíza Gonçalves dos Reis Monteiro
Shigueo Iwamoto
Marlene Freire
Marisa França Ferreira
Marlene Antônia dos Reis
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2017
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-017-0571-0

Other articles of this Issue 1/2017

BMC Nephrology 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.